Limits...
Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.

Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I, Stritzker J, Szalay AA - J Oncol (2010)

Bottom Line: Therefore, there is an urgent need to identify novel agents for therapy of this disease.Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors.In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA.

ABSTRACT
Canine mammary carcinoma is a highly metastatic tumor that is poorly responsive to available treatment. Therefore, there is an urgent need to identify novel agents for therapy of this disease. Recently, we reported that the oncolytic vaccinia virus GLV-1h68 could be a useful tool for therapy of canine mammary adenoma in vivo. In this study we analyzed the therapeutic effect of GLV-1h68 against canine mammary carcinoma. Cell culture data demonstrated that GLV-1h68 efficiently infected and destroyed cells of the mammary carcinoma cell line MTH52c. Furthermore, after systemic administration, this attenuated vaccinia virus strain primarily replicated in canine tumor xenografts in nude mice. Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors. In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.

No MeSH data available.


Related in: MedlinePlus

Western blot analysis of virus-mediated expression of Renilla luciferase-GFP fusion protein and β-galactosidase. MTH52c cells infected with GLV-1h68 at MOIs of 0.1 (a) and 1.0 (b) were used for protein isolation at 1, 12, 24, 48, 72, and 96 hours post infection (hpi). The time-dependent expression of Renilla luciferase-GFP fusion protein (Ruc-GFP), β-galactosidase (LacZ), and beta-actin as a control was analyzed as described in Materials and Methods.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2902752&req=5

fig2: Western blot analysis of virus-mediated expression of Renilla luciferase-GFP fusion protein and β-galactosidase. MTH52c cells infected with GLV-1h68 at MOIs of 0.1 (a) and 1.0 (b) were used for protein isolation at 1, 12, 24, 48, 72, and 96 hours post infection (hpi). The time-dependent expression of Renilla luciferase-GFP fusion protein (Ruc-GFP), β-galactosidase (LacZ), and beta-actin as a control was analyzed as described in Materials and Methods.

Mentions: To verify the infection and replication of GLV-1h68 in canine carcinoma cells, we followed the expression of the virus-mediated Renilla luciferase—green fluorescent protein—fusion protein (Ruc-GFP) and β-galactosidase (LacZ) in cell culture (Figure 2). Our Western blot analysis revealed that both marker proteins were efficiently expressed over a period of four days (Figure 2). The expression of Ruc-GFP and LacZ in cells infected at MOI of 0.1 peaked between 48 and 96 hpi, whereas maximum expression with an MOI of 1.0 was around 48 hpi.


Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.

Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I, Stritzker J, Szalay AA - J Oncol (2010)

Western blot analysis of virus-mediated expression of Renilla luciferase-GFP fusion protein and β-galactosidase. MTH52c cells infected with GLV-1h68 at MOIs of 0.1 (a) and 1.0 (b) were used for protein isolation at 1, 12, 24, 48, 72, and 96 hours post infection (hpi). The time-dependent expression of Renilla luciferase-GFP fusion protein (Ruc-GFP), β-galactosidase (LacZ), and beta-actin as a control was analyzed as described in Materials and Methods.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2902752&req=5

fig2: Western blot analysis of virus-mediated expression of Renilla luciferase-GFP fusion protein and β-galactosidase. MTH52c cells infected with GLV-1h68 at MOIs of 0.1 (a) and 1.0 (b) were used for protein isolation at 1, 12, 24, 48, 72, and 96 hours post infection (hpi). The time-dependent expression of Renilla luciferase-GFP fusion protein (Ruc-GFP), β-galactosidase (LacZ), and beta-actin as a control was analyzed as described in Materials and Methods.
Mentions: To verify the infection and replication of GLV-1h68 in canine carcinoma cells, we followed the expression of the virus-mediated Renilla luciferase—green fluorescent protein—fusion protein (Ruc-GFP) and β-galactosidase (LacZ) in cell culture (Figure 2). Our Western blot analysis revealed that both marker proteins were efficiently expressed over a period of four days (Figure 2). The expression of Ruc-GFP and LacZ in cells infected at MOI of 0.1 peaked between 48 and 96 hpi, whereas maximum expression with an MOI of 1.0 was around 48 hpi.

Bottom Line: Therefore, there is an urgent need to identify novel agents for therapy of this disease.Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors.In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA.

ABSTRACT
Canine mammary carcinoma is a highly metastatic tumor that is poorly responsive to available treatment. Therefore, there is an urgent need to identify novel agents for therapy of this disease. Recently, we reported that the oncolytic vaccinia virus GLV-1h68 could be a useful tool for therapy of canine mammary adenoma in vivo. In this study we analyzed the therapeutic effect of GLV-1h68 against canine mammary carcinoma. Cell culture data demonstrated that GLV-1h68 efficiently infected and destroyed cells of the mammary carcinoma cell line MTH52c. Furthermore, after systemic administration, this attenuated vaccinia virus strain primarily replicated in canine tumor xenografts in nude mice. Finally, infection with GLV-1h68 led to strong inflammatory and oncolytic effects resulting in significant growth inhibition of the tumors. In summary, the data showed that the GLV-1h68 virus strain has promising potential for effective treatment of canine mammary carcinoma.

No MeSH data available.


Related in: MedlinePlus